The Alzheimer International Society is dedicated to foster the global effort to end Alzheimer's disease. The Society serves as the coordinating hub to interconnect with scientific, academic, government and industry thought-leaders and key stakeholders worldwide.

Alzheimer’s disease (AD) is a devastating neurological disorder that affects more than 44 million people worldwide. Alzheimer's disease afflicts 5.7 million people in the United States alone, at an annual cost of $216 billion in 2017, according to the Alzheimer's Association.

Without a therapeutic breakthrough, the number of Americans with Alzheimer's disease is expected to double to 13.4 million patients in the USA and 100 million patients worldwide by 2050. A new Alzheimer case will develop every 33 seconds, and the projected costs will reach $1.2 billion. About 3 percent of men and women ages 65 to 74 have Alzheimer's disease, and nearly half of those age 85 and older may have the disease.

Alzheimer's disease is characterized by the destruction of neurons that produce acetylcholine, a neurotransmitter present in the cerebral cortex. This causes impaired memory, judgement, and the ability to reason.

Currently marketed drugs for AD do not prevent or reverse this disease and are approved only for the management of symptoms. Driven by the clear unmet medical need and a better understanding of the biology and pathophysiology of AD, the number of drugs in development for this indication has increased dramatically in recent years.

No current there is no disease-modifying treatment has been approved for Alzheimer's disease.

CLINICAL TRIALS

The Alzheimer International Society offers a free, easy-to-use clinical studies matching service that generates customized lists of studies based on your conditions. Working with other non-profit organizations, pharmaceutical companies and government agencies, we have an updated database contains more than 300 clinical trials in many countries around the world.

By participating in a clinical trial, you can help yourself while providing valuable insight into potential treatments and methods of prevention. Your participation will help to test new drug therapy to accelerate the process of finding a cure to end Alzheimer’s disease. We need your help to advance research.

The first step to find a suitable clinical trial for you, please contact us. Please rest assured that information you provide us will be treated in strict confidential.